IDBS and Alchemi announced a partnership designed to speed up regulated biopharma submissions by connecting AI agents to data governed inside the IDBS Polar platform. The focus is on regulatory filings where CMC teams spend months assembling data, rebuilding process histories, and drafting compliance-heavy technical documents. Alchemi’s agent workflow is positioned as “human-in-the-loop,” generating submission-ready CMC technical reports, clinical study reports, and dossier components while keeping a compliance trail intact through governed data at the point of creation. The companies cited customer deployments where documents can be produced up to 70% faster using the AI agents. The partnership targets one of the most persistent friction points in lifecycle operations: moving faster without breaking validation, traceability, or auditability. For sponsors, the practical impact is narrower than broad AI adoption headlines—this is about rewriting and routing compliance outputs through established systems and workflows. If it performs at scale, the partnership could shorten the time from data lock to dossier assembly and reduce manual reconstruction.